Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects

References

• Behm Dillon DM, Penzak SR, Bailey Klepser T. The use of herbals by patients with HIV. Adv Pharmacy 2004;2:41–60
   Google Scholar
• Fairfield KM, Eisenberg DM, Davis RB, et al. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med 1998;158:2257–64
   PubMed Web of Science ®Google Scholar
• Hsiao AF, Wong MD, Kanouse DE, et al. Complementary and alternative medicine use and substitution for conventional therapy by HIV-infected patients. J Acquir Immune Defic Syndr 2003;33:157–65
   PubMed Web of Science ®Google Scholar
• Weber K, Schneider M, Sacks H, et al. Trends in complementary/alternative medicine (CAM) use in a large cohort of HIV infected women in the US from 1994–2001. Barcelona: XIV International AIDS Conference, 2002: Abstract WePeB6004
   Google Scholar
• Piscitelli SC, Burstein, AH, Chaitt D, et al. Indinavir concentrations and St. John’s wort. Lancet 2000;355:547–8
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234–8
   PubMed Web of Science ®Google Scholar
• Jellin JM. Natural Medicines Comprehensive Database. Therapeutic Research Faculty, Stockton, CA. Available at www.naturaldatabase.com [Last accessed 3 October 2007]
   Google Scholar
• Blumenthal, M. The Complete German Commission E Monographs, Therapeutic Guide to Herbal Medicines. Austin: American Botanical Council, 1998
   Google Scholar
• Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273–82
   PubMed Web of Science ®Google Scholar
• Kubota Y, Kobayashi K, Tanaka N, et al. Interaction of Ginkgo biloba extract (GBE) with hypotensive agent, nicardipine, in rats. In Vivo 2003;17:409–12
   PubMed Web of Science ®Google Scholar
• Shinozuka K, Umegaki K, Kubota Y, et al. Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci 2002;70:2783–92
   PubMed Web of Science ®Google Scholar
• Penzak SR. Mechanisms of drug interactions 2: transport proteins. In: Stephen C. Piscitelli, Keith A. Rodvold, eds. Drug Interactions in Infectious Diseases, 2nd edn. Totowa, NJ: Humana Press, 2005
   Google Scholar
• Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11–20
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003;63:769–802
   PubMed Web of Science ®Google Scholar
• Kleijnen J, Knipschild P. Ginkgo biloba. Lancet 1992;340:1136–9
   PubMed Web of Science ®Google Scholar
• American Herbal Pharmacopoeia. Gingko Leaf & Ginkgo Leaf Dry Extract Monograph. Santa Cruz: American Herbal Pharmacopoeia, 2003
   Google Scholar
• Product Information: Kaletra®, lopinavir and ritonavir. Abbott Laboratories, North Chicago, Illinois, USA, 2000
   Google Scholar
• Lim ML, Min SS, Eron JJ, et al. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr 2004;36:1034–40
   PubMed Web of Science ®Google Scholar
• Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52–60
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Walker A, Isoherranen N, et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 2007;82:410–26
   PubMed Web of Science ®Google Scholar
• Chen M, Ma L, Drusano GL, et al. Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther 2006;80:531–38
   PubMed Web of Science ®Google Scholar
• Morse GD, Rosenkranz S, Para MF, et al. Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals. Antimicrob Agents Chemother 2004;49:3373–81
   Web of Science ®Google Scholar
• Gallicano K, Khaliq Y, Carignan G, et al. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2001;70:149–58
   PubMed Web of Science ®Google Scholar
• Indiana University School of Medicine. Cytochrome P450 Drug Interaction Table. Available at: http://medicine.iupui.edu/flockhart/table.htm [Last accessed 02 August, 2007]
   Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb–drug interactions in humans. Clin Pharmacol Ther 2002;72:276–87
   PubMed Web of Science ®Google Scholar
• Streetman DS, Bertino JS, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10: 187–216
   Google Scholar
• Rogers JF, Nafziger AN, Kashuba AD, et al. Single plasma concentrations of 1’-hydroxymidazolam or the ratio of 1’-hydroxymidazolam : midazolam do not predict midazolam clearance in healthy subjects. J Clin Pharmacol 2002;42:1079–82
   PubMed Web of Science ®Google Scholar
• Eap CB, Buclin T, Cucchia G, et al. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 2004;60:237–46
   PubMed Web of Science ®Google Scholar
• Lin YS, Lockwood GF, Graham MA, et al. In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 2001;11:781–91
   PubMedGoogle Scholar
• Nafziger AN, Bertino JS Jr. Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis. Clin Pharmacol Ther 2007;82:379.
   PubMed Web of Science ®Google Scholar
• Smith M, Lin KM, Zheng YP. An open trial of nifedipine–herb interactions: nifedipine with St. John’s wort, ginseng, or ginkgo biloba [abstract]. Clin Pharmacol Ther 2001;69:86
   Google Scholar
• Uchida S, Yamada H, Dong Li X, et al. Effects of Ginkgo biloba extract on the pharmacokinetics and dynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006;46:1290–8
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. Am J Health Syst Pharm 2000;57:963–9
   Google Scholar